This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

10 Biotech Stocks With A History Of Beating Earning Expectations

3. Targacept, Inc. (TRGT): Engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. Market cap at $160.99M, most recent closing price at $4.79.In Dec 2011: Reported EPS at -0.29 vs. estimate at -0.3 (surprise of 3.3%). In Mar 2012: Reported EPS at 0.07 vs. estimate at -0.25 (surprise of 128%). In Jun 2012: Reported EPS at 0.43 vs. estimate at 0.4 (surprise of 7.5%). In Sep 2012: Reported -0.24 vs. estimate at -0.41 (surprise of 41.5%. [Average earnings surprise at 45.07%].

 

4. Osiris Therapeutics, Inc. (OSIR): Focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. Market cap at $297.89M, most recent closing price at $9.06.In Dec 2011: Reported EPS at 0.15 vs. estimate at 0.11 (surprise of 36.4%). In Mar 2012: Reported EPS at -0.04 vs. estimate at -0.09 (surprise of 55.6%). In Jun 2012: Reported EPS at -0.13 vs. estimate at -0.15 (surprise of 13.3%). In Sep 2012: Reported -0.09 vs. estimate at -0.14 (surprise of 35.7%. [Average earnings surprise at 35.25%].

 

5. Array BioPharma, Inc. (ARRY): Focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Market cap at $489.99M, most recent closing price at $4.34.In Dec 2011: Reported EPS at -0.06 vs. estimate at -0.12 (surprise of 50%). In Mar 2012: Reported EPS at -0.11 vs. estimate at -0.16 (surprise of 31.2%). In Jun 2012: Reported EPS at -0.09 vs. estimate at -0.13 (surprise of 30.8%). In Sep 2012: Reported -0.13 vs. estimate at -0.15 (surprise of 13.3%. [Average earnings surprise at 31.33%].

 

6. YM BioSciences Inc. (YMI: Engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Market cap at $455.32M, most recent closing price at $2.89.In Dec 2011: Reported EPS at -0.06 vs. estimate at -0.07 (surprise of 14.3%). In Mar 2012: Reported EPS at -0.05 vs. estimate at -0.07 (surprise of 28.6%). In Jun 2012: Reported EPS at -0.04 vs. estimate at -0.06 (surprise of 33.3%). In Sep 2012: Reported -0.05 vs. estimate at -0.07 (surprise of 28.6%. [Average earnings surprise at 26.2%].

 

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,942.97 -17.60 -0.10%
S&P 500 1,975.08 -3.26 -0.16%
NASDAQ 4,436.0230 -13.5410 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs